Coral Drugs audit report | Rephine

The following Rephine audit reports are available for Coral Drugs:

Coral Drugs


To get more information on audit reports by Rephine, please click the green button below to get contacted by Rephine!

 

What is a Coral Drugs audit report?

Here you can find the GMP Audit Report for Coral Drugs.

This audit report is accessible to other pharmaceutical companies, providing a detailed evaluation of Coral Drugs's compliance with industry standards and regulations. What makes this report stand out? It's a deep dive into the company's operations, spotlighting their stringent adherence to industry norms, evidenced by certifications like GMP, CEP, DMF.

An audit report in the pharmaceutical realm is more than a mere document; it's a mirror reflecting a company's commitment to regulatory compliance, quality control, and internal policies. This report isn't just a checklist – it's a narrative showcasing how Coral Drugs aligns with the highest standards of Good Manufacturing Practices (GMP) and beyond. It doesn't just highlight compliance; it uncovers potential areas for enhancement, offering pathways for continuous improvement.


When do you need an audit report?

Utilizing this report means it's no longer necessary to audit this supplier yourself. The availability of this report demonstrates Coral Drugs's commitment to transparency and adherence to quality standards. It serves as a valuable tool for businesses looking to partner with or procure services from Coral Drugs, ensuring a well-informed and secure decision-making process. For further details and to access the full Coral Drugs GMP Audit Report contact us.

Pharmaoffer is dedicated to enhancing transparency and trust within the pharmaceutical industry, and this report is a key component of that mission. Would you like to learn more about it, click here and someone from the Rephine team will reach out to you.

How much does an audit report cost?

The cost of a Good Manufacturing Practice (GMP) audit report can vary significantly based on several factors. Here's a general overview: 

  • Complexity of the Facility: The more complex the manufacturing processes and facilities, the more in-depth the audit will be, leading to higher costs.

  • Industry and Product Type: Certain industries, like pharmaceuticals, biotechnology, and food, have stringent GMP requirements, which can make audits more expensive due to the specialized knowledge and thoroughness required.

  • Location of the Facility: Geographical location can impact costs due to travel expenses for the auditors, local economic conditions, and regulatory variations.

  • Audit Duration: The length of time needed to complete the audit also plays a role. A larger facility or one with more complex processes may require more time to audit thoroughly.

  • Scope of the Audit: The specific requirements of the GMP audit (like whether it's for the entire organization or specific processes) can affect the price.

For a precise and detailed quotation that is specifically tailored to the Coral Drugs’s facility and operational scope, we encourage you to contact Rephine directly.

Rephine APIs on Pharmaoffer

Global experts in quality assurance & GxP compliance.

Providing specialists quality assurance services for more than 25 years.

Highly qualified experts operating across the globe

Our services:

GMP Audit Services
Third party audits
GxP Consultancy
Quality Assurance
Regulatory Compliance

Response time:

Coral Drugs


Coral Drugs is headquartered in New Delhi, India. We are proud to be an international leader in the pharmaceutical industry, specializing in the production of active pharmaceutical ingredients (API's) across multiple therapeutic segments including antineoplastics, steroids, non-steroids, hormones, and beta-agonists. Our global reach and high production standards have earned us a reputation for quality and reliability.

Our love of science is demonstrated by our goal to maximize the production of API’s by discovering new and safer ways to manufacture without compromising quality.


With a team of dedicated scientists, Coral’s R&D department provides efficient processes for off-patent products. By constantly evaluating new drugs for production, we demonstrate our ability to meet challenges in different pharmaceutical industry segments.

Our founder, Mr. B.K. Bhuwania, started the company with a clear vision to make a difference and to offer products complying with the highest quality. Those principles are still applicable in our lives, even today, as we conduct our operations.